Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GMP update

This article was originally published in The Tan Sheet

Executive Summary

Dietary supplement good manufacturing practices should not be expected to come out before the end of the year, "but certainly we should be able to get them out shortly after that," according to FDA Associate Commissioner for Regulatory Affairs Margaret O'K. Glavin. "It's really important those GMPs get out and get out expeditiously. [Center of Food Safety & Applied Nutrition Director] Bob Brackett chatted with me last week about this and how interested he is in making sure those are out there. They're important to us; they're important to you," she stressed at the Council for Responsible Nutrition's annual conference Sept. 18. O'K. Glavin encouraged members of the supplement industry to voice their desire for GMPs to regulators. "Certainly if you would continue to make known your strong desire to get those issued, that would not hurt in the least." She emphasized that regulatory processes are slow, "but where there is this confluence of the regulatory agency and the regulated industry both interested in getting them out that should make a huge difference"...

You may also be interested in...



Dietary Supplement GMPs Back To FDA; Publication Expected In June

Dietary supplement good manufacturing practices have received final clearance by the Office of Management and Budget, OMB and FDA confirmed May 9

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099782

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel